We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Read MoreHide Full Article
Key Takeaways
INSM shares plunged nearly 20% after the phase IIb BiRCh study missed both primary and secondary endpoints.
Insmed ended Brinsupri development in CRSsNP after no benefit versus placebo despite good tolerability.
INSM acquired INS1148 from Opsidio and plans mid-stage studies in interstitial lung disease and asthma.
Shares of Insmed (INSM - Free Report) lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a mid-stage study evaluating Brinsupri (brensocatib) in chronic rhinosinusitis without nasal polyps (CRSsNP).
This phase IIb study, called BiRCh, failed to achieve either its primary or secondary efficacy endpoints. Although the drug was well-tolerated in patients, the results did not show any treatment benefit in patients compared with placebo, even at the highest dose level. Based on this outcome, Insmed decided to end development of Brinsupri in CRSsNP.
This announcement surprised investors, who had been expecting positive results from the BiRCh study. Insmed had achieved a significant milestone with Brinsupri in August, when the FDA approved it as the first treatment for non-cystic fibrosis (non-CF) bronchiectasis. Post this approval, it became the second marketed product in Insmed’s portfolio after Arikayce (approved to treat a rare lung disease infection).
Early commercial traction for Brinsupri has been encouraging — the drug generated $28 million in third-quarter 2025 sales despite receiving approval only in the middle of the quarter, reflecting strong initial uptake. Investors had expected this momentum to be further propelled by potential approval in new indications, such as CRSsNP, which have significant commercial potential.
The BiRCh study results have also made investors less enthused about the phase II CEDAR study, which is evaluating Brinsupri in the hidradenitis suppurativa (HS) indication. An update on this study is expected in the first half of 2026.
INSM Stock Performance
This marks the first major setback for Insmed in some time, as the company had delivered a series of positive updates leading up to this announcement. Following the sharp after-hours decline, the stock continued to trend lower in pre-market trading today.
Year to date, shares of Insmed are still up 187% compared with the industry’s 18% growth.
Image Source: Zacks Investment Research
Insmed Expands Pipeline With New Acquisition
Alongside the BiRCh study results, Insmed announced that it has acquired an investigational monoclonal antibody, INS1148 (formerly OpSCF), from the privately-held biotech Opsidio. This drug is designed to address respiratory and immunological and inflammatory diseases by targeting a specific isoform of Stem Cell Factor SCF248.
Insmed plans to initially develop INS1148 in mid-stage studies for interstitial lung disease and moderate-to-severe asthma.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $7.29 to $7.56. EPS estimates for 2026 have increased from $7.81 to $8.08 during the same period. Year to date, shares of ANIP have surged 49%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88. CRMD shares have risen 41% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.04%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Key Takeaways
Shares of Insmed (INSM - Free Report) lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a mid-stage study evaluating Brinsupri (brensocatib) in chronic rhinosinusitis without nasal polyps (CRSsNP).
This phase IIb study, called BiRCh, failed to achieve either its primary or secondary efficacy endpoints. Although the drug was well-tolerated in patients, the results did not show any treatment benefit in patients compared with placebo, even at the highest dose level. Based on this outcome, Insmed decided to end development of Brinsupri in CRSsNP.
This announcement surprised investors, who had been expecting positive results from the BiRCh study. Insmed had achieved a significant milestone with Brinsupri in August, when the FDA approved it as the first treatment for non-cystic fibrosis (non-CF) bronchiectasis. Post this approval, it became the second marketed product in Insmed’s portfolio after Arikayce (approved to treat a rare lung disease infection).
Early commercial traction for Brinsupri has been encouraging — the drug generated $28 million in third-quarter 2025 sales despite receiving approval only in the middle of the quarter, reflecting strong initial uptake. Investors had expected this momentum to be further propelled by potential approval in new indications, such as CRSsNP, which have significant commercial potential.
The BiRCh study results have also made investors less enthused about the phase II CEDAR study, which is evaluating Brinsupri in the hidradenitis suppurativa (HS) indication. An update on this study is expected in the first half of 2026.
INSM Stock Performance
This marks the first major setback for Insmed in some time, as the company had delivered a series of positive updates leading up to this announcement. Following the sharp after-hours decline, the stock continued to trend lower in pre-market trading today.
Year to date, shares of Insmed are still up 187% compared with the industry’s 18% growth.
Image Source: Zacks Investment Research
Insmed Expands Pipeline With New Acquisition
Alongside the BiRCh study results, Insmed announced that it has acquired an investigational monoclonal antibody, INS1148 (formerly OpSCF), from the privately-held biotech Opsidio. This drug is designed to address respiratory and immunological and inflammatory diseases by targeting a specific isoform of Stem Cell Factor SCF248.
Insmed plans to initially develop INS1148 in mid-stage studies for interstitial lung disease and moderate-to-severe asthma.
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #3 (Hold).
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are ANI Pharmaceuticals (ANIP - Free Report) and CorMedix (CRMD - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $7.29 to $7.56. EPS estimates for 2026 have increased from $7.81 to $8.08 during the same period. Year to date, shares of ANIP have surged 49%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88. CRMD shares have risen 41% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.04%.